Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
LEIDEN, the Netherlands, March 01, 2016 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA), today announced details about the Research & Development Day to be held on Monday, March 14, 2016 in New York, NY, USA starting at 10am ET. Daniel de Boer, Chief Executive Officer of ProQR will also take part in an analyst led fireside chat at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 at the Loews Miami Beach Hotel in Miami Beach, FL, USA at 2:35pm ET.
R&D Day
On March 14, 2016 starting at 10am ET the company will highlight a selection of programs in its growing pipeline including programs in CF, LCA, Usher syndrome, Fuchs endothelial corneal dystrophy, Alzheimer’s disease and dystrophic epidermolysis bullosa. The day will feature presentations from ProQR executives and scientific staff as well as from Key Opinion Leaders in the different therapeutic areas.
ProQR speakers:
- Daniel de Boer, Chief Executive Officer
- Noreen Henig, M.D., Chief Development Officer
- Peter Adamson, Ph.D., Head of Ophthalmology Research
- Gerard Platenburg, Chief Innovation Officer
KOL speakers:
- Bob Beall, Ph.D., former President of the Cystic Fibrosis Foundation
- Pete Coffey, Professor of Ocular Biology and Therapeutics at UCL Institute of Ophthalmology, UK
- Brett Kopelan, Executive Director of the Dystrophic EB Research Association of America
- Thomas Wisniewski, M.D., Director of the Alzheimer Disease Centre NY
Kindly RSVP to Ronen Abergel at [email protected] to reserve a seat or for additional information.
Webcasts
The live webcasts of both events will be accessible from the ‘Investor Relations’ section of ProQR’s website under ‘Events and Presentations’. The archived webcasts will be available for 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.
Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
[email protected]
